ORPHAN DRUGS ASSESMENT IN FRANCE: ACCEPTABILITY OF THE CLINICAL DATA FOR THE ECONOMIC EVALUATION

被引：0
|
作者：
Bodaghi, C. [1 ]
Monnier, R. [2 ]
Bourguignon, S. [1 ]
Korchagina, D. [1 ]
机构：
[1] IQVIA, Paris, France
[2] IQVIA, CAPIONIS, Bordeaux 33, France
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDG29
引用
收藏
页码：S601 / S601
页数：1
相关论文
共 50 条
  • [1] PHARMACOECONOMIC EVALUATION OF ORPHAN DRUGS IN THE UNITED KINGDOM, FRANCE, ITALY, TURKEY AND EXPLORATION OF THE EVALUATION PROCESS OF ORPHAN DRUGS IN ALGERIA
    Kebaili, H.
    Djahdou, Z.
    Amrani, I
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S235 - S235
  • [2] REIMBURSEMENT OF ORPHAN DRUGS UNDER EARLY BENEFIT ASSESMENT IN GERMANY
    Ecker, T.
    Schneider, D.
    Bot, D.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A281 - A281
  • [3] Patient access to orphan drugs in France
    Marion Bourdoncle
    Blandine Juillard-Condat
    Florence Taboulet
    [J]. Orphanet Journal of Rare Diseases, 14
  • [4] Patient access to orphan drugs in France
    Bourdoncle, Marion
    Juillard-Condat, Blandine
    Taboulet, Florence
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2019, 14 (1)
  • [5] DO DISEASE SEVERITY AND/OR QUALITY OF CLINICAL DATA INFLUENCE PRICING POLICY IN FRANCE? AN ANALYSIS ON ORPHAN DRUGS AND BLOOD CANCERS TREATMENTS
    Vandewalle, C.
    Charoy, M.
    Heurtebis, J.
    Desplanches, L.
    Gauthier, M.
    de Sauvebeuf, C.
    [J]. VALUE IN HEALTH, 2018, 21 : S191 - S192
  • [6] HTA ASESSMENT COMPARISON OF ORPHAN DRUGS IN FRANCE AND GERMANY
    Remuzat, C.
    Mzoughi, O.
    Rodrigues, J.
    Korchagina, D.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A236 - A237
  • [7] Determinants of orphan drugs prices in France: a regression analysis
    Daria Korchagina
    Aurelie Millier
    Anne-Lise Vataire
    Samuel Aballea
    Bruno Falissard
    Mondher Toumi
    [J]. Orphanet Journal of Rare Diseases, 12
  • [8] ORPHAN DRUGS IN FRANCE: KEY MARKET ACCESS INCENTIVES
    Mennezein, L.
    Avot, D.
    Laigle, V
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A565 - A565
  • [9] ORPHAN DRUGS: WHAT FACTORS IMPACT THE PRICE IN FRANCE?
    De Joannis, P. E.
    Borget, I
    [J]. VALUE IN HEALTH, 2019, 22 : S784 - S785
  • [10] PRICE LIFE CYCLE MANAGEMENT OF ORPHAN DRUGS IN FRANCE
    Lebreton, C.
    Avot, D.
    Morand, F.
    Laigle, V
    Troubat, A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A660 - A660
12345